Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 42.6% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, up 40.98% year-over-year, with the annual reading at $3.3 million for FY2025, 40.98% up from the prior year.
  • Depreciation & Amortization (CF) hit $1.0 million in Q4 2025 for Perspective Therapeutics, up from $775000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.0 million in Q4 2025 to a low of -$78000.0 in Q4 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $364947.4 across 5 years, with a median of $259000.0 in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): crashed 310.81% in 2021 and later skyrocketed 286.57% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at -$78000.0 in 2021, then soared by 276.92% to $138000.0 in 2022, then soared by 118.84% to $302000.0 in 2023, then skyrocketed by 134.77% to $709000.0 in 2024, then skyrocketed by 42.6% to $1.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CATX at $1.0 million in Q4 2025, $775000.0 in Q3 2025, and $733000.0 in Q2 2025.